TY - JOUR
T1 - Genetic variants in the genes encoding rho GTPases and related regulators predict cutaneous melanoma-specific survival
AU - Liu, Shun
AU - Wang, Yanru
AU - Xue, William
AU - Liu, Hongliang
AU - Xu, Yinghui
AU - Shi, Qiong
AU - Wu, Wenting
AU - Zhu, Dakai
AU - Amos, Christopher I.
AU - Fang, Shenying
AU - Lee, Jeffrey E.
AU - Hyslop, Terry
AU - Li, Yi
AU - Han, Jiali
AU - Wei, Qingyi
N1 - Publisher Copyright:
© 2017 UICC
PY - 2017/8/15
Y1 - 2017/8/15
N2 - Rho GTPases control cell division, motility, adhesion, vesicular trafficking and phagocytosis, which may affect progression and/or prognosis of cancers. Here, we investigated associations between genetic variants of Rho GTPases-related genes and cutaneous melanoma-specific survival (CMSS) by re-analyzing a published melanoma genome-wide association study (GWAS) and validating the results in another melanoma GWAS. In the single-locus analysis of 36,018 SNPs in 129 Rho-related genes, 427 SNPs were significantly associated with CMSS (p < 0.050 and false-positive report probability <0.2) in the discovery dataset, and five SNPs were replicated in the validation dataset. Among these, four SNPs (i.e., RHOU rs10916352 G > C, ARHGAP22 rs3851552 T > C, ARHGAP44 rs72635537 C > T and ARHGEF10 rs7826362 A > T) were independently predictive of CMSS (a meta-analysis derived p = 9.04 × 10−4, 9.58 × 10−4, 1.21 × 10−4 and 8.47 × 10−4, respectively). Additionally, patients with an increasing number of unfavorable genotypes (NUGs) of these loci had markedly reduced CMSS in both discovery dataset and validation dataset (ptrend=1.47 × 10−7 and 3.12 × 10−5). The model including the NUGs and clinical variables demonstrated a significant improvement in predicting the five-year CMSS. Moreover, rs10916352C and rs3851552C alleles were significantly associated with an increased mRNA expression levels of RHOU (p = 1.8 × 10−6) and ARHGAP22 (p = 5.0 × 10−6), respectively. These results may provide promising prognostic biomarkers for CM personalized management and treatment.
AB - Rho GTPases control cell division, motility, adhesion, vesicular trafficking and phagocytosis, which may affect progression and/or prognosis of cancers. Here, we investigated associations between genetic variants of Rho GTPases-related genes and cutaneous melanoma-specific survival (CMSS) by re-analyzing a published melanoma genome-wide association study (GWAS) and validating the results in another melanoma GWAS. In the single-locus analysis of 36,018 SNPs in 129 Rho-related genes, 427 SNPs were significantly associated with CMSS (p < 0.050 and false-positive report probability <0.2) in the discovery dataset, and five SNPs were replicated in the validation dataset. Among these, four SNPs (i.e., RHOU rs10916352 G > C, ARHGAP22 rs3851552 T > C, ARHGAP44 rs72635537 C > T and ARHGEF10 rs7826362 A > T) were independently predictive of CMSS (a meta-analysis derived p = 9.04 × 10−4, 9.58 × 10−4, 1.21 × 10−4 and 8.47 × 10−4, respectively). Additionally, patients with an increasing number of unfavorable genotypes (NUGs) of these loci had markedly reduced CMSS in both discovery dataset and validation dataset (ptrend=1.47 × 10−7 and 3.12 × 10−5). The model including the NUGs and clinical variables demonstrated a significant improvement in predicting the five-year CMSS. Moreover, rs10916352C and rs3851552C alleles were significantly associated with an increased mRNA expression levels of RHOU (p = 1.8 × 10−6) and ARHGAP22 (p = 5.0 × 10−6), respectively. These results may provide promising prognostic biomarkers for CM personalized management and treatment.
KW - GTPase-activating protein
KW - Rho GTPase
KW - cutaneous melanoma-specific survival
KW - genome-wide association study
UR - http://www.scopus.com/inward/record.url?scp=85020071983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020071983&partnerID=8YFLogxK
U2 - 10.1002/ijc.30785
DO - 10.1002/ijc.30785
M3 - Article
C2 - 28510328
AN - SCOPUS:85020071983
SN - 0020-7136
VL - 141
SP - 721
EP - 730
JO - International journal of cancer
JF - International journal of cancer
IS - 4
ER -